ストックスクリーナーアプリを入手
10.89
0.00%
0.00
アフターアワーズ：
10.67
-0.22
-2.02%
Satellos Bioscience Inc (MSLE) 最新ニュース
Satellos Bioscience raises $57.2 million in public offering By Investing.com - Investing.com Nigeria
Satellos Bioscience Completes $57.2 Million Public Offering - marketscreener.com
Satellos Closes US$57.2 Million Public Offering in Canada and the United States - marketscreener.com
Satellos Brief: Closes US$57.2M Public Offer in Canada and United States, Including Exercise of Underwriters' Option to Purchase Additional Shares - marketscreener.com
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares - Business Wire
Satellos Bioscience Inc.Common Stock (NQ: MSLE - FinancialContent
(MSCL) Equity Market Report (MSCL:CA) - Stock Traders Daily
Satellos prices $50M public offering - MSN
Satellos Raises US$50 Million in Cross-Border Offering as Shares Debut on Nasdaq - TipRanks
Satellos Bioscience prices $50 million public offering - Investing.com
Canadian Investment Regulatory Organization Trading HaltMSCL - marketscreener.com
Satellos announces pricing of US$50 million public offering in Canada and the United States - marketscreener.com
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States - Business Wire
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Applicati - PharmiWeb.com
Satellos announces launch of public offering in Canada and the United States and filing of application to list on Nasdaq - marketscreener.com
Satellos launches public offering, applies for Nasdaq listing - MSN
Satellos Plans Cross-Border Share Offering and Nasdaq Listing to Fund Muscle Disease Pipeline - TipRanks
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq - marketscreener.com
(MSCL) Advanced Trading Insights (MSCL:CA) - Stock Traders Daily
(MSCL) Strategic Equity Report (MSCL:CA) - Stock Traders Daily
Satellos appoints Antoinette Paone as chief development officer and head of Regulatory Affairs - marketscreener.com
Satellos appoints Antoinette Paone as chief development officer By Investing.com - Investing.com Australia
Satellos Bioscience Taps Antoinette Paone as Chief Development Officer - Contract Pharma
Satellos Strengthens Executive Bench With Veteran Regulator as Duchenne Program Advances - TipRanks
Satellos Biosciences Brief: Appointing Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs - marketscreener.com
Satellos Bioscience Welcomes New Chief Development Officer - GuruFocus
(MSCL) Technical Pivots with Risk Controls (MSCL:CA) - Stock Traders Daily
Satellos Bioscience Brief: Announcing Share Consolidation in Connection with Proposed Nasdaq Listing - marketscreener.com
Satellos announces share consolidation in connection with proposed Nasdaq listing - marketscreener.com
(MSCL) Advanced Equity Analysis (MSCL:CA) - Stock Traders Daily
(MSCL) Technical Data (MSCL:CA) - Stock Traders Daily
(MSCL) Stock Analysis and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy - BioSpace
Satellos receives FDA clearance for phase 2 Duchenne trial - Investing.com
Satellos Tackles Duchenne ‘As Stem Cell People Solving a Stem Cell Problem’ - Citeline News & Insights
Satellos to Participate in December Investor Conferences - Business Wire
Does DMD start in the womb? New research challenges old beliefs. - Muscular Dystrophy News
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy - BioSpace
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors - BioSpace
Oral therapy moves to follow-up after strong data in DMD adults - Muscular Dystrophy News
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy - Investing News Network
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy - BioSpace
Satellos asks FDA to clear Phase 2 trial of DMD treatment - Muscular Dystrophy News
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress - Investing News Network
Doubled Grip Strength: Satellos' Novel DMD Drug Heads to Phase 2 Trial After Promising Adult Results - stocktitan.net
Satellos to Participate in Four September Institutional and Retail Investor Conferences - Investing News Network
Here's Why We're Watching Satellos Bioscience's (TSE:MSCL) Cash Burn Situation - Yahoo Finance
Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy (TSX:MSCL:CA) - Seeking Alpha
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones - Investing News Network
Encouraging Results from Phase 1 Trials, Says Satellos Chief Scientific Officer. Now It's On to Phase 2 - Managed Healthcare Executive
DMD treatment SAT-3247 safe in trial, shows early signs of efficacy - Muscular Dystrophy News
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy - BioSpace
Bloom Burton & Co. Inc. Announces Exercise of Satellos Bioscience Inc. Warrants - TMX Newsfile
A new approach to treating Duchenne muscular dystrophy - Drug Discovery News
CCORF Maintains SATELLOS BIOSCIENCE INC(MSCLF.US) With Buy Rating, Maintains Target Price $0.87 - 富途牛牛
Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - BioSpace
Phase 1 trial of DMD treatment finishes enrolling healthy volunteers - Muscular Dystrophy News
Satellos Bioscience price target raised to C$1.25 from C$1 at Canaccord - Nasdaq
Satellos Bioscience Secures Massive $40M Equity Offering for Phase 2 Clinical Development - stocktitan.net
Satellos’ AAK1 inhibitor regenerates muscle in dogs - BioWorld MedTech
Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247 - Business Wire
SAT-3247 adds rare pediatric disease designation - BioWorld MedTech
Satellos files in Australia to begin clinical testing of SAT-3247 for Duchenne muscular dystrophy - BioWorld MedTech
Full FDA clearance for Elevidys in DMD boosts Sarepta shares - BioWorld MedTech
Satellos Bioscience Inc. Opens the Market - Newswire Canada
Mechanism of Action of SAT-3247 in Muscular Dystrophy: Frank Gleeson - NeurologyLive
SAT-3247 increases muscle force in mouse models of muscle degeneration - BioWorld MedTech
SAT-3247 improves muscle function in FSHD mouse model - Muscular Dystrophy News
SAT-3247 improves skeletal muscle function in mouse model of facioscapulohumeral muscular dystrophy - BioWorld MedTech
Satellos Bioscience Announces 2023 Q3 Financial Results and Operational Highlights - Chartmill
Satellos to Present at the Piper Sandler 35th Annual Healthcare Conference - Chartmill
Satellos Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program - Chartmill
Satellos to Present at the Stifel 2023 Healthcare ConferenceChartmill - Chartmill
0.10%
7.16%
大文字化:
|
ボリューム (24 時間):